[go: up one dir, main page]

WO1992008474A3 - Traitement des maladies pulmonaires - Google Patents

Traitement des maladies pulmonaires Download PDF

Info

Publication number
WO1992008474A3
WO1992008474A3 PCT/GB1991/002049 GB9102049W WO9208474A3 WO 1992008474 A3 WO1992008474 A3 WO 1992008474A3 GB 9102049 W GB9102049 W GB 9102049W WO 9208474 A3 WO9208474 A3 WO 9208474A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
provides
cyclosporin
corticosteroids
identified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1991/002049
Other languages
English (en)
Other versions
WO1992008474A2 (fr
Inventor
Anthony Barry Kay
Neil Christopher Barnes
Peter John Cole
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Heart and Lung Institute
Original Assignee
National Heart and Lung Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909025154A external-priority patent/GB9025154D0/en
Application filed by National Heart and Lung Institute filed Critical National Heart and Lung Institute
Publication of WO1992008474A2 publication Critical patent/WO1992008474A2/fr
Publication of WO1992008474A3 publication Critical patent/WO1992008474A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Physiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Le ciblage pharmacologique spécifique des lymphocytes T constitue une nouvelle approche pour le traitement de l´asthme chronique (à la fois chez les patients relativement sensibles aux effets des corticoïdes et chez les patients résistant à leurs effets) et pour le traitement d'autres maladies pulmonaires telles que la bronchestasie et la mucovicidose, ainsi que la sinusite. Dans cette invention, on utilise de la cyclosporine A et d'autres agents immunosuppresseurs suivant le même mode ou lieu d'action ou suivant un mode ou un lieu d'action similaire, pour traiter des maladies se caractérisant par l'obstruction de l'écoulement de l'air et/ou une sinusite chronique. D'autres agents appropriés comprennent le FK 506, la répamicyne et des anticorps anti-CD4 rendus assimilables pour l'homme. Cette invention concerne également un test in vitro permettant de prédire la réponse clinique aux corticoïdes et aux agents immunosuppresseurs. A l'aide du test in vitro on peut détecter la résistance aux corticoïdes et on peut ainsi identifier les patients résistant aux corticoïdes qui peuvent être traités avec de la cyclosporine A ou un autre agent immunosuppresseur approprié.
PCT/GB1991/002049 1990-11-20 1991-11-20 Traitement des maladies pulmonaires Ceased WO1992008474A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB909025154A GB9025154D0 (en) 1990-11-20 1990-11-20 Treatment of lung diseases
GB9025154.7 1990-11-20
GB9026620.6 1990-12-07
GB909026620A GB9026620D0 (en) 1990-11-20 1990-12-07 Treatment of lung diseases

Publications (2)

Publication Number Publication Date
WO1992008474A2 WO1992008474A2 (fr) 1992-05-29
WO1992008474A3 true WO1992008474A3 (fr) 1992-06-25

Family

ID=26297977

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1991/002049 Ceased WO1992008474A2 (fr) 1990-11-20 1991-11-20 Traitement des maladies pulmonaires

Country Status (2)

Country Link
AU (1) AU8910891A (fr)
WO (1) WO1992008474A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300129B1 (en) * 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US6770279B1 (en) 1992-10-08 2004-08-03 The Kennedy Institute Of Rheumatology TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
DE69312077T2 (de) * 1992-10-08 1997-10-30 Kennedy Inst Of Rheumatology Behandlung von autoimmun- und entzundungskrankheiten
US5707622A (en) * 1994-03-03 1998-01-13 Genentech, Inc. Methods for treating ulcerative colitis
US5874080A (en) * 1994-03-03 1999-02-23 Genentech, Inc. Anti-IL-8 monoclonal antibodies for treatment of asthma
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
ES2206590T3 (es) * 1995-09-19 2004-05-16 Fujisawa Pharmaceutical Co., Ltd. Composiciones en aerosol.
GB9702944D0 (en) * 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
AUPP223198A0 (en) * 1998-03-06 1998-04-02 Fujisawa Pharmaceutical Co., Ltd. New use
EP1100495A4 (fr) * 1998-07-28 2002-09-25 Smithkline Beecham Corp Propenamides tenant lieu de modulateurs de ccr5
GB9818278D0 (en) * 1998-08-22 1998-10-14 Smith & Nephew Compositions
JP2002538170A (ja) * 1999-03-02 2002-11-12 セントコール， インコーポレイテッド 喘息の治療における抗−ＴＮＦα抗体
JP2006517217A (ja) * 2003-02-10 2006-07-20 ノバルティス アクチエンゲゼルシャフト コルチコイドおよび／またはカルシニューリン阻害剤耐性疾患を処置するための、コルチコイドおよび免疫抑制剤を含んでなる医薬組合せ剤
TW200509958A (en) * 2003-02-14 2005-03-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
WO2005030252A1 (fr) * 2003-09-23 2005-04-07 Pdl Biopharma, Inc. Traitement de maladies respiratoires avec des anticorps diriges contre le recepteur de l'interleukine-2
WO2005063242A1 (fr) * 2003-12-30 2005-07-14 Astellas Pharma Inc. Utilisation de macrolides pour le traitement ou la prevention de l'obstruction bronchique
EP1874118A4 (fr) * 2005-04-27 2009-07-22 Univ Florida Materiaux et methodes permettant d'ameliorer la degradation de proteines mutantes associees avec une maladie humaine
CA2638774C (fr) 2006-03-31 2015-11-24 Medarex, Inc. Animaux transgeniques exprimant des anticorps chimeriques destines a etre utilises pour la preparation d'anticorps humains
US8398972B2 (en) 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
TWI434854B (zh) 2007-11-13 2014-04-21 Evec Inc 結合ｈＧＭ－ＣＳＦ的單株抗體以及包含其之醫學組成物

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Dialog Information Services, file 155, Medline, 66- 92, Dialog Accession No. 06229897, Lagrue G. et al.: "Membranoproliferative glomerulonephritis assosiciated with Buckley's syndrome treated with cyclosporin. Glomerulonephrite membrano-proliferative associee a un syndrome de Buckley traitee par la ciclosporine", & Presse Med Apr 11 1987, 16 (13) p619-21 *
Dialog Information Services, file 155, Medline, 66-92, Dialog Accession No. 07458632, Fukuda T.: "Inhibition of antigen-induced late asthmatic response and bronchial hyperresponsiveness by cyclosporin A", & Arerugi May 1990, & Arerugi May 1990, 39 (5) p483-7 *
Dialog Information Services, file 155, Medline, 66-92, Dialog Accession No. 07590095, Fukuda T. et al: "The role of eosinophils, neutrophils and lymphocytes for the development of bronchial hyperresponsiveness in a guinea pig model of asthma", & Nippon Kyobu Shikkan Gakkai Zasshi Oct 1990, 28 (10)p128 8-93 *
Dialog Information Services, file 155, Medline, 66-92, Dialog Accession No. 07858952, Szczeklik A. et al: "Cyclosporin for steroid-dependentasth ma", & Allergy May 1991, 46 (4) p312-5 *
Dialog Information Services, file 155, Medline, 66-92, Dialog Accession No. 07902257, Fukuda T. et al: "Inhibition of antigen-induced late asthmatic response and bronchial hyperresponsiveness by cyclosporin and FK 506", & Int Arch Allergy Appl Immunol (SWITZERLAND) 1991, 94 (1-4) p259-61 *
Dialog Information Services, file 5, BIOSIS, 69-92, Dialog Accession No. 4856115, Pedersen C. et al.: "Inhibitory effect of cyclosporin A on histamine release from human leukocytes and rat mast cells", & Allergy (COPENH) 40 (2), 1985, 103-107 *
Dialog Information Services, file 5, BIOSIS, 69-92, Dialog Accession No. 7905334, Finnerty N.A. et al.: "Effect of cyclosporine on corticosteroid dependent asthma", & J Allergy Clin Immunol 87 (1 part 2), 1991, 297 *

Also Published As

Publication number Publication date
WO1992008474A2 (fr) 1992-05-29
AU8910891A (en) 1992-06-11

Similar Documents

Publication Publication Date Title
WO1992008474A3 (fr) Traitement des maladies pulmonaires
Epstein et al. Time course of hemosiderin production by alveolar macrophages in a murine model
Wardlaw et al. Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils.
US5837713A (en) Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids
Ip et al. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty
JP3434824B2 (ja) 例えばｎ−（３−オキシヘキサノイル）ホモセリンラクトンのような免疫抑制剤及び抗アレルギー性化合物
Fujisawa et al. The neutrophil and chronic allergic inflammation
ITMI912296A0 (it) Nuovi pregna 1,4-diene-3,20.dione-16,17-acetal-21-esteri, procedimento per la loro preparazione, composizione e metodi per il trattamento di stati infiammatori
Paolieri et al. Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human continuous cell lines
AP2000001805A0 (en) Use of antifungal agents for the topical treatment of fungus-induced mucositis.
WO2005099776A3 (fr) Agents limitant les effets steroidiens et methodes d'utilisation associees
RU2004123463A (ru) Стероидные сапогенины и их производные для лечения болезни
CY2009010I1 (el) Μεθοδος για εμπλουτισμο r-επιμερους 16,17-ακεταλης παραγωγων των 21-ακυλοξυ πρεγνα-1,4-διεν-11.βητα., 16.αλφα., 17.αλφα.-τριολ-3,20-διονης
BR9811823A (pt) Método e composições para tratar reações alérgicas de fase tardia e doenças inflamatórias
Patella et al. Protein Fv produced during vital hepatitis is a novel activator of human basophils and mast cells.
Moqbel et al. The effect of platelet-activating factor on IgE binding to, and IgE-dependent biological properties of, human eosinophils
Dalakas The role of high-dose immune globulin intravenous in the treatment of dermatomyositis
CA2268305A1 (fr) Utilisation d'un inhibiteur de h+, k+-atpase dans le traitement de polypes du nez
WO2001082953A3 (fr) Methodes de traitement de maladies associees a une inflammation dans le cadre des pathologies non ischemiques
Säwe et al. Glucuronidation of morphine in human liver and interaction with oxazepam
Mehindate et al. Induction of chemokine gene expression by major histocompatibility complex class II ligands in human fibroblast-like synoviocytes. Differential regulation by interleukin-4 and dexamethasone.
Skowron et al. Alternating and intermittent regimens of zidovudine (3′-azido-3′-deoxythymidine) and dideoxycytidine (2′, 3′-dideoxycytidine) in the treatment of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex
Muhlfelder et al. Glucocorticoids inhibit the generation of leukocyte procoagulant (tissue factor) activity
AU2703297A (en) New derivatives of pregnane with no substituent in position 17-alpha, their use as medicaments, their preparation process, the intermediates of this process and the compositions containing them
Briggs et al. Plasma lipoprotein changes during oral contraception

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MC MG MN MW NL NO PL RO SD SE SU US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MC MG MN MW NL NO PL RO SD SE SU US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA